Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft

Bone Marrow Transplantation

Volumn 47, Issue 2, 2012, Pages 277-282

  Hasskarl, J ^a   Zerweck, A ^a   Wasch R ^a   Ihorst, G ^a   Bertz, H ^a   Finke, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

donor lymphocyte infusion; efficacy; frozen; G CSF; GvHD; stimulated

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CRYOPRESERVATION; DONOR LYMPHOCYTE INFUSION; FEASIBILITY STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SURVIVAL TIME; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84857032054     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.45     Document Type: Article

References (28)

1. Savani BN, Mielke S, Reddy N, Goodman S, Jagasia M, Rezvani K. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant 2009; 44: 769-777.
2. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405-412. (Pubitemid 34072522)
3. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
4. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
5. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-1562. (Pubitemid 26034083)
6. Riddell SR, Murata M, Bryant S, Warren EH. T-cell therapy of leukemia. Cancer Control 2002; 9: 114-122. (Pubitemid 34457330)
7. Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25: 4938-4945. (Pubitemid 350225492)
8. Lee JH, Lee KH, Kim S, Seol M, Kim SH, Kim WK et al. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation. Leuk Res 2001; 25: 305-312. (Pubitemid 32185763)
9. Choi SJ, Lee JH, Kim S, Seol M, Lee YS, Lee JS et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 2004; 18: 1789-1797. (Pubitemid 39530008)
10. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444. (Pubitemid 27074209)
11. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: the long and winding road: how should it be traveled? Bone Marrow Transplant 2008; 42: 569-579.
12. Alyea EP. Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect. Best Pract Res Clin Haematol 2008; 21: 239-250. (Pubitemid 351712716)
13. Raiola AM, Van Lint MT, Valbonesi M, Lamparelli T, Gualandi F, Occhini D et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003; 31: 687-693. (Pubitemid 36553479)
14. Verdonck LF, Petersen EJ, Lokhorst HM, Nieuwenhuis HK, Dekker AW, Tilanus MG et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant 1998; 22: 1057-1063. (Pubitemid 28554214)
15. Simula MP, Marktel S, Fozza C, Kaeda J, Szydlo RM, Nadal E et al. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia 2007; 21: 943-948. (Pubitemid 46672070)
16. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS et al. A pilot study of cytoreductive chemotherapy combined with infusion of additional peripheral blood stem cells reserved at time of harvest for transplantation in case of relapsed hematologic malignancies after allogeneic peripheral blood stem cell transplant. Bone Marrow Transplant 2004; 33: 231-236. (Pubitemid 38180938)
17. Sohn SK, Baek JH, Kim DH, Jung JT, Kwak DS, Park SH et al. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL. Am J Hematol 2000; 65: 75-80. (Pubitemid 30659980)
18. Sohn SK, Jung JT, Kim DH, Lee NY, Seo KW, Chae YS et al. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer 2002; 94: 18-24.
19. Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hemato-logic malignancies. Blood 2008; 112: 415-425.
20. Grullich C, Bertz H, Spyridonidis A, Muller CI, Finke J. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. Bone Marrow Transplant 2008; 41: 845-850. (Pubitemid 351766592)
21. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003; 21: 1480-1484. (Pubitemid 46594099)
22. Wasch R, Reisser S, Hahn J, Bertz H, Engelhardt M, Kunzmann R et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant 2000; 26: 243-250. (Pubitemid 30614402)
23. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
24. Sairafi D, Remberger M, Uhlin M, Ljungman P, Ringden O, Mattsson J. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. Biol Blood Marrow Transplant 2010; 16: 1728-1737.
25. Wasch R, Bertz H, Kunzmann R, Finke J. Incidence of mixed chimaerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation. Br J Haematol 2000; 109: 743-750. (Pubitemid 30609751)
26. Klingebiel T, Bader P. Delayed lymphocyte infusion in children given SCT. Bone Marrow Transplant 2008; 41(Suppl 2): S23-S26. (Pubitemid 351864702)
27. le Coutre P, Kreuzer KA, Massenkeil G, Baskaynak G, Zschieschang P, Genvresse I et al. Autologous peripheral blood stem cell transplantation of stem cells harvested in imatinib-induced complete cytogenetic remission: an example of in vivo purging in CML. Leukemia 2003; 17: 2525-2526. (Pubitemid 38072594)
28. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767-776. (Pubitemid 38129531)